Slide 1: Financial Results Year Ended 31 December 2022
Financial Results Year Ended 31 December 2022
Slide 2: Vita Life Sciences Ltd
VITA LIFE SCIENCES LTD Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the development and distribution of over the counter (OTC) medicines, as well as complementary and alternative medicines, dietary s
Slide 3: Commentary
COMMENTARY Record Group sales at $66.9m, up 17% on previous A$’m GROUP SALES A$’m 12 GROUP EBIT corresponding period (PCP) reflecting the impact of increased 80 11 channels of distribution and higher consumer demand, particularly 10 across the immunity segment. 60 9 The increase in sales was fro
Slide 4: Australia
AUSTRALIA Record revenue of $37.3m an increase of 23% on previous corresponding period (PCP). A$’m Revenue up 23% A$’m EBIT down 10% 40 6 35 Domestic revenue remains strong with around 20% growth on 5 30 PCP with the ongoing pharmacy expansion and strong 25 4 consumer offtake. 20 3 15 10 2 Full
Slide 5: Malaysia
MALAYSIA Record revenue of $21.4m an increase of 11% on PCP. A$’m Revenue up 11% A$’m EBIT up 3% 22 20 7 Increased consumer demand domestically for both 6 18 VitaHealth and Herbs of Gold brands underpinned the 5 growth across this market. 16 4 14 3 12 2 The Malaysian market continues to demons
Slide 6: Singapore
SINGAPORE Revenue of $5.8m an increase of 4% on PCP following A$’m Revenue up 4% A$’m EBIT down 1 improvements in consumer demand. 6 0.8 5 Singapore was slower to recover post COVID due to low levels 4 0.6 of tourism. 3 0.4 Full Year Full Year 2022 2021 2022 2021 FULL YEAR FINANCIAL RESULTS | FO
Slide 7: Other Asia
OTHER ASIA Revenue of $ 2.3m, an increase of 15% on PCP driven mostly by growth A$’m Revenue up 15% in Vietnam. 3 2.5 2 Vietnam remains a key strategic market albeit the challenging trading 1.5 conditions following the end of the Covid-19 restrictions. 1 0.5 0 Full Year EBIT was around $0.3m.
Slide 8: Final Dividend & Cashflows
FINAL DIVIDEND & CASHFLOWS Decrease in gross operating cashflow conversion to EBITDA of 62%. This was mainly due to higher stock Gross operating Final dividend purchase/ holding levels. cashflow to EBITDA per share 100% 3.3 80% 3.2 A higher dividend payout compared to the PCP. 60% 3.1 40% 3 Fu
Slide 9: Priorities & Outlook
PRIORITIES & OUTLOOK Expand the 3-year brand building investment strategy to drive higher consumer and retailer engagement via multiple channels. Continue the execution of an educational and digitally led marketing strategy to support the brands premium product positioning. Leverage the Group’
Slide 10: Appendix
APPENDIX ET
Slide 11: Full Year Results
FULL YEAR RESULTS Income Statement for the year ended Dec 2022 2021 $’m $’m Revenue 66.9 57.1 EBITDA 11.2 11.6 EBIT 10.6 11.2 Profit before tax 10.7 11.2 Profit after tax 7.3 8.2 EPS (Basic – cents/ share) 13.37 15.75 Dividend (cents / share) 6.00 5.75 FULL YEAR FINANCIAL RESULTS | FOR THE 12 MONTHS
Slide 12: Balance Sheet
BALANCE SHEET Balance Sheet as at Dec 2022 2021 $’m $’m Current assets 41.2 35.1 Non-current assets 10.6 10.2 Total assets 51.8 45.3 Current liabilities 14.9 14.5 Non-current liabilities 0.4 0.4 Total Liabilities 15.3 14.9 Net Assets 36.5 30.4 FULL YEAR FINANCIAL RESULTS | FOR THE 12 MONTHS TO 31 DE
Slide 13: Cash Flow
CASH FLOW Cash Flow for the year ended Dec 2022 2021 $’m $’m Receipts from customers 69.0 60.2 Payments to suppliers and employees (62.0) (51.4) Gross operating cash flow 7.0 8.8 EBITDA 11.2 11.6 Gross operating cash flow / EBITDA 62.5% 75.4% Net interest 0 0 Income tax paid (4.3) (2.9) Operating ca
Slide 14: Contacts
CONTACTS Contact: Mr Chin L Khoo, Chief Financial Officer: 0450 734 526 Mr Andrew O’Keefe, Managing Director: 0448 882 556 Office Telephone : +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232, AUSTRALIA FULL YE
Slide 15: Disclaimer
DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a